Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Sage Therapeutics is a late-stage biopharmaceutical company dedicated to discovering, developing, and delivering life-changing medicines for people with brain health disorders. Their R&D efforts focus on modulating two critical central nervous system receptor systems, GABA and NMDA. Sage aims to address unmet medical needs in areas such as depression, neurology, and neuropsychiatry by leveraging its expertise in brain circuitry and neurosteroids. Their first commercial product, ZURZUVAE™ (zuranolone), co-developed and co-commercialized with Biogen, is approved for postpartum depression in the U.S.
The Cambridge headquarters serves as the central hub for Sage's executive leadership, research and development operations, clinical development, commercial strategy, and corporate administrative functions. It is the primary site for strategic decision-making and scientific innovation.
The headquarters is situated in a modern life sciences facility in Kendall Square, offering state-of-the-art laboratory and office spaces. Its location provides close proximity to leading academic institutions like MIT and Harvard, numerous other biotech companies, and venture capital firms, fostering collaboration and innovation.
Sage Therapeutics promotes a work culture centered on patients, driven by science, and built on collaboration. They emphasize values such as courage, passion, and urgency, aiming to create an inclusive environment where employees are empowered to make a difference in brain health.
The Cambridge headquarters' location in Kendall Square is highly significant, placing Sage at the epicenter of biopharmaceutical research and development. This provides unparalleled access to top talent, cutting-edge research, potential partnerships, and a vibrant scientific community, crucial for a company focused on neuroscience innovation.
While Sage Therapeutics' primary operational base, including its headquarters for research, development, and corporate functions, is in Cambridge, Massachusetts, USA, its impact and activities extend globally. The company conducts multinational clinical trials to support drug development and regulatory submissions in various countries. For its commercialized products, like ZURZUVAE™, it collaborates with partners (e.g., Biogen) that have established global commercial capabilities. Sage's engagement with the international scientific and medical community is also a key aspect of its global reach.
215 First Street
Cambridge
Massachusetts
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Sage Therapeutics' leadership includes:
Sage Therapeutics has been backed by several prominent investors over the years, including:
Over the past 12 months (approx. May 2023 - May 2024), Sage Therapeutics has undergone notable executive transitions, including a key retirement in R&D leadership, the appointment of a new Chief Development Officer, and departures of other senior executives as part of strategic realignments and company evolution.
Discover the tools Sage Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Sage Therapeutics commonly utilizes the email format [first].[last]@sagerx.com. For instance, an employee named Jane Doe would likely have the email address jane.doe@sagerx.com. While this is a frequently observed pattern, other formats might be used in specific cases or for different departments.
[first].[last]@sagerx.com
Format
jane.doe@sagerx.com
Example
75%
Success rate
Sage Therapeutics Investor Relations • May 7, 2024
Sage Therapeutics announced its financial results for the first quarter of 2024, providing updates on the U.S. commercial launch of ZURZUVAE™ (zuranolone) for postpartum depression, progress in its pipeline programs including dalzanemdor (SAGE-718) and SAGE-324, and reiterated financial guidance....more
Sage Therapeutics Press Release • January 4, 2024
Sage Therapeutics outlined its key pipeline objectives for 2024 and announced a strategic reorganization, including a workforce reduction, aimed at enhancing operational efficiency and focusing resources on priority programs to drive future growth and value....more
Sage Therapeutics Press Release • August 4, 2023
Sage Therapeutics and its partner Biogen received FDA approval for ZURZUVAE™ (zuranolone) as the first oral medication specifically for adults with postpartum depression. Concurrently, the FDA issued a Complete Response Letter for the New Drug Application for zuranolone in major depressive disorder, indicating that additional studies are needed for that indication....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Sage Therapeutics, are just a search away.